Novocure has been working for a long time to establish the market for its device-based cancer treatment based on Tumor Treating Fields (TTF). Its Optune system was first approved by FDA in 2011 to treat glioblastoma (GBM) after chemotherapy, in the fall of 2015 it was kicked up to a first-line GBM treatment for adults in combination with chemotherapy temozolomide.